BioNTech SE (BNTX) Financial Statements & Analysis

BioNTech SE (BNTX) Income Statement

BioNTech SE reported revenue of EUR 2.76B in fiscal 2025 (fiscal year ended Dec 31, 2025), up 0.2% from EUR 2.75B a year earlier. BioNTech SE posted a net loss of EUR 1.09B, compared with a net loss of EUR 665.30M a year earlier. Gross margin was 77.6% and operating margin -22.6%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was EUR 105.60M, down 59.5% from the same quarter a year earlier.

BioNTech SE Income Statement Analysis

Values in billions EUR

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

BioNTech SE income statement - Annual data in billions EUR
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Mar 2020	Dec 2018	Dec 2017
Revenue & Gross Profit
Revenue	2.76	2.75	3.82	17.31	18.98	0.48	0.11	0.13	0.06
Cost of Revenue	0.62	0.54	0.60	3.00	2.91	0.06	0.02	0.01	0.01
Gross Profit	2.14	2.35	3.22	14.32	16.07	0.42	0.09	0.11	0.05
Operating Expenses
Research & Development	2.02	2.25	1.78	1.54	0.95	0.65	0.23	0.14	0.09
Selling, General & Administrative	0.70	0.60	0.59	0.54	0.33	0.11	0.04	0.03	0.03
Operating Expenses	2.76	3.66	2.34	2.01	1.14	0.74	0.27	0.17	0.11
Operating Income	-0.62	-1.31	0.88	12.30	14.93	-0.32	-0.18	-0.05	-0.06
Other Income/Expense
Interest Income	0.25	0.66	0.36	0.05	0.00	0.00	0.00	0.00	0.00
Interest Expense	0.01	-0.02	0.01	0.02	0.01	0.00	0.00	0.00	0.00
Other Income/Expense	-0.39	0.64	0.32	0.67	0.15	-0.02	0.00	0.01	-0.02
Income
Income Before Tax	-1.01	-0.68	1.19	12.95	15.05	-0.15	-0.18	-0.05	-0.09
Income Tax Expense	0.08	-0.01	0.26	3.52	4.75	-0.16	0.00	0.00	0.00
Net Income	-1.09	-0.67	0.93	9.43	10.29	0.02	-0.18	-0.05	-0.09
Net Income - Continuous Operations	-1.09	-0.67	0.93	9.43	10.29	0.02	-0.18	-0.05	-0.09
Net Income - Discontinued Operations	-	-	-	-	-	-	-	-	-
EBITDA	-0.63	-1.17	1.38	13.10	15.00	-0.29	-0.14	-0.02	-0.07
EBIT	-1.27	-1.29	1.19	12.97	14.93	-0.32	-	-	-
Depreciation & Amortization	0.37	0.11	0.18	0.12	0.01	0.03	0.03	0.02	0.01
Earnings Per Share
Basic EPS	-5.00	-3.00	4.00	39.00	42.00	-	-1.00	-	-
Diluted EPS	-5.00	-3.00	4.00	38.00	40.00	-	-1.00	-	-
Basic Shares Outstanding	0.24	0.24	0.24	0.24	0.24	0.24	0.21	0.23	0.23
Diluted Shares Outstanding	0.24	0.24	0.24	0.25	0.26	0.25	0.21	0.23	0.23

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About BioNTech SE Financial Statements

What was BioNTech SE's revenue in fiscal 2025?

BioNTech SE reported revenue of EUR 2.76B in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 0.2% from EUR 2.75B a year earlier.

Is BioNTech SE profitable?

No. BioNTech SE reported a net loss of EUR 1.09B in fiscal 2025. In fiscal 2024 it lost EUR 665.30M.

What is BioNTech SE's operating margin?

BioNTech SE's operating income was −EUR 623.87M on revenue of EUR 2.76B in fiscal 2025, an operating margin of -22.6%, compared with -47.8% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition